DRKS00024635招募中不适用
Analyzing the incidence of SARS-Cov-2 infected children and teenager in Western Pomerania - COVIDKID Vorpommern
niversitätsmedizin Greifswald0 个研究点目标入组 4,000 人开始时间: 2021年3月9日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 4,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 6 Months 至 17 Years（—）
- 性别
- All
入选标准
- •permanent residency in Western Pomerania
排除标准
- •permanent residency outside of Western Pomerania, no informed consent
研究者
相似试验
已完成
不适用
Survey on prevalence of SARS-CoV-2 infection in health care workers, working at large-scale medical institutionsCoronavirus Disease-2019(COVID-19, SARS-CoV-2 infection)JPRN-UMIN000043538Yokohama City University500
尚未招募
不适用
Assessment of Risks of corona virus Infection in Health Care Workers at a Tertiary Cancer Care Centre With COVID Care FacilityCTRI/2021/01/030213Tata Memorial Hospital
已完成
不适用
Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA)COVID-19NCT04355338Butantan Institute3,520
已完成
不适用
Consequences of COVID-19 on the respiratory, coagulation, immune and endocrine system and association with bacterial infections among patients treated in the intensive care unit.COVID-19Respiratory infectionRenin-angiotensin-aldosterone system dysfunctionInfection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesBlood - Clotting disordersMetabolic and Endocrine - Metabolic disordersMetabolic and Endocrine - Other endocrine disordersInflammatory and Immune System - Other inflammatory or immune system disordersRenal and Urogenital - Kidney diseaseAcute kidney injuryCoagulation disordersACTRN12621001300864Patrycja Lesnik, MD, PhD132
招募中
2 期
Incidence rate of SARS-CoV-2 infection, risk factors, and safety after BBIBP-CorV COVID-19 vaccine in adolescent in Thailand.Incident rate, risk factor of infection, and safety profile after complete of 2 dose of the BBIBP-CorV COVID-19 vaccine in adolescent in Thai population.COVID-19 vaccine, Sinopharm, adolescent, safety, incident rate, risk factors.TCTR20210920006Chulabhorn Royal Academy50,000